Beta-Blocker Exposure Tied to Neonatal Hypoglycemia, Bradycardia
Babies born to mothers exposed to beta-blockers are more likely to have neonatal hypoglycemia and bradycardia.
HealthDay News -- Neonates born to mothers exposed to beta-blockers at the time of delivery have increased risk of neonatal hypoglycemia and bradycardia, according to a study published in online in Pediatrics.
Brian T. Bateman, MD, from Brigham and Women's Hospital, Boston, Massachusetts, and colleagues used data from 2 292 116 completed pregnancies linked to live-born infants of Medicaid-enrolled women from 2003 to 2007 to examine the risks of neonatal hypoglycemia and neonatal bradycardia associated with maternal exposure to beta-blockers. The authors controlled for potential confounders using propensity score matching.
The researchers identified 10 585 pregnancies that were exposed to beta-blockers at the time of delivery. The risk of neonatal hypoglycemia was 4.3% and 1.2% in the beta-blocker-exposed and unexposed neonates, respectively. Risk remained elevated for neonatal hypoglycemia and bradycardia among exposed vs unexposed pregnancies after adjustment for confounders (adjusted odds ratios, 1.68 and 1.29, respectively).
"Our findings suggest that neonates born to mothers exposed to beta-blockers in late pregnancy, including labetalol, are at elevated risk for neonatal hypoglycemia and bradycardia," the researchers wrote.
Disclosures: Several authors disclosed financial ties to the pharmaceutical industry.